Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
– PDUFA date set for November 26, 2018 – STAMFORD, Conn., May 29, 2018 (GLOBE NEWSWIRE) -- Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company innovating the development of highly...
-
– LOXO-292 Phase 1 Clinical Trial Abstract Selected for “Best of ASCO” – – Company to Host Conference Call and Webcast on Saturday, June 2nd at 4:00 p.m. CT – STAMFORD, Conn., May 16, 2018 (GLOBE...
-
- LOXO-292 Phase 1 Oral Presentation Upcoming at 2018 ASCO Annual Meeting - - LOXO-292 Preclinical and Clinical Proof-of-Concept Data Published in Annals of Oncology - - Rolling Submission for...
-
STAMFORD, Conn., May 07, 2018 (GLOBE NEWSWIRE) -- Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company innovating the development of highly selective medicines for patients with...
-
STAMFORD, Conn., May 01, 2018 (GLOBE NEWSWIRE) -- Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company innovating the development of highly selective medicines for patients with...
-
- Expands Illumina’s Oncology Offerings for NextSeq™ 550Dx with a Companion Diagnostic Version of TruSight™ Tumor 170 for Solid Tumors - - Loxo Oncology to Utilize a Companion Diagnostic Version of...
-
STAMFORD, Conn., April 04, 2018 (GLOBE NEWSWIRE) -- Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company innovating the development of highly selective medicines for patients with...
-
STAMFORD, Conn., March 26, 2018 (GLOBE NEWSWIRE) -- Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company innovating the development of highly selective medicines for patients with...
-
STAMFORD, Conn., March 06, 2018 (GLOBE NEWSWIRE) -- Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company innovating the development of highly selective medicines for patients with...
-
– Larotrectinib Rolling NDA Submission on Track for Completion in March – – LOXO-292 Phase 1 Clinical Data Update Expected in First Half 2018 – STAMFORD, Conn., March 01, 2018 (GLOBE NEWSWIRE) --...